Soufflé Therapeutics raised $135 million in venture capital to advance at least three oligonucleotide medicines in development, according to the report. The financing extends the runway for a company emerging from the gene-regulatory pipeline space where delivery and repeat dosing durability are key development determinants. The round’s size signals that investors continue to back RNA-centered platforms and chemistries that can drive clinically relevant target modulation with manageable safety and manufacturability. For oligonucleotide therapeutics, late-stage execution often depends on tissue targeting and dose economics rather than only potency. While specific asset targets and trial timelines were not fully detailed in the snippet, the company’s ability to fund multiple programs suggests a deliberate strategy to diversify both mechanism and therapeutic area while refining delivery. Dealmakers will watch how Soufflé uses the capital to close the translational gap—especially through expanded IND-enabling work, formulation optimization, and biomarker-driven dose finding.